Quinazoline derivatives and their use in the treatment of thrombocythemia

Abstract

A method for the treatment of thrombocythemia in a subject comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or equilibrating forms thereof.

1 . A substantially pure form of a compound of the formula 
     
       
         
         
             
             
         
       
     
     an equilibrating form thereof, a pharmaceutically acceptable salt of the compound or of the equilibrating form thereof,
 wherein, 
 R1 is H, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  alkoxy, or 
 C 6-10  aryl; 
 R2 is 
 
     
       
         
         
             
             
         
       
       R3 is OH, Halogen, SH, O—C 1-6  alkyl or an hydroxymimetic group; and 
       X and Y are independently H or halogen. 
     
   
   
       2 . A compound of  claim 1 , wherein the compound has the formula 
     
       
         
         
             
             
         
       
     
   
   
       3 . The compound of  claim 2 , wherein R2 is 
     
       
         
         
             
             
         
       
     
   
   
       4 . The compound of  claim 2 , wherein R1 is H or C 1-6  alkyl. 
   
   
       5 . The compound of  claim 2 , wherein R1 is H. 
   
   
       6 . The compound of  claim 2 , wherein X is H or halogen. 
   
   
       7 . The compound of  claim 2 , wherein Y is H or Cl. 
   
   
       8 . The compound of  claim 2 , wherein X is Cl. 
   
   
       9 . The compound of  claim 2 , wherein Y is Cl. 
   
   
       10 . The compound of  claim 1 , wherein the compound is 
     
       
         
         
             
             
         
       
     
   
   
       11 . A method for the treatment of thrombocythemia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 . 
   
   
       12 . The method of  claim 11 , wherein the thrombocythemia is associated with essential thrombocythemia (ET), chronic myelogenous leukemia (CML), polycythemia vera (PV), agnogenic myeloid metaplasia (AMM) or sickle cell anemia (SCA). 
   
   
       13 . A method for the treatment of thrombocythemia comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined in  claim 10 . 
   
   
       14 . The method of  claim 13  wherein the thrombocythemia is associated with essential thrombocythemia (ET), chronic myelogenous leukemia (CML), polycythemia vera (PV), agnogenic myeloid metaplasia (AMM) or sickle cell anemia (SCA). 
   
   
       15 . A composition comprising at least one compound as defined in  claim 1  and at least one therapeutic agent chosen from anagrelide, hydroxyurea, P 32 , busulphan, aspirin, clopidogrel, α-interferon ticlopidine and dipyridamole.